Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Business Overview: The Company manufactures and distributes apparatus, instruments, and consumables for life science research. Operations are divided into the Apparatus and Instrumentation Business segment (continuing operations) and the Capital Equipment Business segment (discontinued operations, held for sale). The Company is actively pursuing a strategy of organic growth and "tuck-under" acquisitions while divesting the underperforming Capital Equipment segment.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2006 |
Six Months Ended June 30, 2006 |
Six Months Ended June 30, 2005 (As Restated) |
|---|---|---|---|
| Revenues (Continuing Ops) | $18,187 | $35,557 | $32,412 |
| Gross Profit | $9,242 | $18,122 | $15,652 |
| Gross Margin % | 50.8% | 51.0% | 48.3% |
| Operating Income | $2,290 | $4,531 | $3,035 |
| Net Income (Loss) | $(324) | $216 | $(23,514) |
| Cash and Cash Equivalents | $9,849 (as of June 30, 2006) | ||
| Long-Term Debt | $6,500 (Current portion of revolving credit) | ||
| Working Capital | $36,664 (Current Assets $55,156 - Current Liab. $18,492) |
Note: Net income figures include losses from discontinued operations. Income from continuing operations was $1,785 (3 months) and $3,393 (6 months) for 2006.
Material Changes vs. Prior Period
- Revenue Growth: Revenues from continuing operations increased 11.7% ($1.9 million) for the quarter and 9.7% ($3.1 million) for the six months ended June 30, 2006, compared to the prior year periods. Growth was driven by increased demand for pre-clinical testing products and amino acid analyzers, as well as improved international sales.
- Margin Expansion: Gross margin improved to 50.8% (Q2) and 51.0% (YTD) from 49.1% and 48.3% in the prior year, respectively. This was attributed to increased sales volumes, improved product mix, and higher margins on new product introductions.
- Discontinued Operations Impact: The prior year periods (2005) were significantly impacted by the Capital Equipment Business segment, which recorded massive impairment charges ($21.7 million in the first half of 2005). In 2006, the loss from discontinued operations was significantly lower at $2.1 million (Q2) and $3.2 million (YTD), reflecting the absence of the large 2005 impairment charges.
- Stock-Based Compensation: The Company adopted SFAS 123(R) on January 1, 2006. This resulted in a new expense of $0.5 million for the quarter and $0.9 million for the six months ended June 30, 2006, which was not present in the 2005 reported figures.
Guidance, Outlook, and Risks
- Divestiture Strategy: Management anticipates selling the Capital Equipment Business segment in a single transaction prior to the end of the fourth quarter of 2006. Proceeds are intended to repay debt or fund further acquisitions.
- Capital Expenditures: The Company expects to spend between $1.0 million and $2.0 million on capital expenditures for the remainder of 2006.
- Liquidity and Debt: The Company has a $20 million revolving credit facility expiring January 1, 2007. As of June 30, 2006, $6.5 million was drawn, with $13.5 million available (limited to $12.2 million by covenants). Management intends to enter a new facility before expiration.
- Key Risks:
- Credit Facility Default: Selling the Capital Equipment segment requires lender consent. Failure to obtain consent could trigger a default, accelerating all indebtedness.
- Foreign Exchange: Approximately 50% of revenues are from non-U.S. operations. A strengthening U.S. dollar negatively impacted revenue growth in the first half of 2006.
- Acquisition Funding: Continued growth via acquisitions may require raising additional capital through debt or equity, which could dilute existing shareholders.
Investor Verification Checklist
- Divestiture Timeline: Verify the status of the Capital Equipment Business sale and whether lender consent has been secured to avoid credit facility default.
- Debt Renewal: Confirm the status of negotiations for a new revolving credit facility to replace the one expiring January 1, 2007.
- Organic Growth Sustainability: Assess whether the 11.7% revenue growth in Q2 2006 is sustainable without the "tuck-under" acquisitions, given the reliance on specific product lines (pre-clinical testing, amino acid analyzers).
- Stock-Based Compensation Impact: Monitor the ongoing impact of SFAS 123(R) adoption on future operating margins, as this is a recurring non-cash expense not present in prior year comparisons.
- Foreign Currency Exposure: Evaluate the Company's hedging strategy (currently none) given that 50% of revenue is international and currency fluctuations materially affect results.